A Phase 1 interventional study of AG2203L and AG2203E in Acute Bronchitis, sponsored by Ahn-Gook Pharmaceuticals Co.,Ltd. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Ahn-Gook Pharmaceuticals Co.,Ltd · Phase 1, Interventional, and Treatment
This Phase 1 study will evaluate the safety and drug-drug interactions of AG2203L and AG2203E in healthy adult participants. Participants will receive AG2203L and AG2203E alone and in combination during three treatment periods according to one of six randomly assigned treatment sequences.
156 studies on the registry are indexed under Bronchitis; 21 are open to participants now.
This study's enrollment of 36 is below the median of 185 across 105 interventional studies indexed under Bronchitis.
Browse Bronchitis studies →Ahn-Gook Pharmaceuticals Co.,Ltd is the lead sponsor of 24 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AG2203L+AG2203E in Period 1, AG2203L in Period 2, and AG2203E in Period 3.
Drug: AG2203L · Drug: AG2203E · Drug: AG2203L+AG2203E
AG2203E in Period 1, AG2203L+AG2203L in Period 2, and AG2203L in Period 3.
Drug: AG2203L · Drug: AG2203E · Drug: AG2203L+AG2203E
AG2203E in Period 1, AG2203L in Period 2, and AG2203E +AG2203L in Period 3.
Drug: AG2203L · Drug: AG2203E · Drug: AG2203L+AG2203E
AG2203L in Period 1, AG2203E in Period 2, and AG2203E +AG2203L in Period 3.
Drug: AG2203L · Drug: AG2203E · Drug: AG2203L+AG2203E
AG2203L in Period 1, AG2203E +AG2203L in Period 2, and AG2203E in Period 3.
Drug: AG2203L · Drug: AG2203E · Drug: AG2203L+AG2203E
AG2203E +AG2203L in Period 1, AG2203E in Period 2, and AG2203L in Period 3.
Drug: AG2203L · Drug: AG2203E · Drug: AG2203L+AG2203E
Multiple doses of 1 tablet three times daily under fasting conditions, followed by a single dose of 1 tablet once daily under fasting conditions.
Multiple doses of 1 capsule three times daily under fasting conditions, followed by a single dose of 1 capsule once daily under fasting conditions.
Multiple doses of 1 tablet and 1 capsule co-administered three times daily under fasting conditions, followed by a single dose of 1 tablet and 1 capsule co-administered once daily under fasting conditions.
AUCt,ss AG2203L and AG2203E
Time frame: 0~12 hours post-dose
Cmax,ss AG2203L and AG2203E
Time frame: 0~12 hours post-dose
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ahn-Gook Pharmaceuticals Co.,Ltd →